Across TCGA pan-cancer cohorts, ACTBP11 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated ACTBP11 data layer.
The strongest signal is observed in mesothelioma (MESO), where higher ACTBP11 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ACTBP11 expression acts as an unfavorable survival marker, although some lineages such as COAD and UCS show a favorable association.
MESO, KICH, and COAD are the cancer types where ACTBP11 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.